(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
Live Chart Being Loaded With Signals
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder...
Stats | |
---|---|
今日成交量 | 5 255.00 |
平均成交量 | 4 324.00 |
市值 | 69.36M |
EPS | $0 ( 2024-01-26 ) |
Last Dividend | $0.220 ( 2018-02-15 ) |
Next Dividend | $0 ( N/A ) |
P/E | -11.84 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2018-02-28 | Anschutz Philip F | Sell | 12 440 000 | CLASS A COMMON STOCK |
2018-02-28 | Anschutz Philip F | Sell | 23 708 639 | CLASS B COMMON STOCK |
2018-02-28 | Campbell Michael L | Sell | 703 660 | Class A Common Stock |
2018-02-28 | Yemenidjian Alex | Sell | 21 880 | Class A Common Stock |
2018-02-28 | Tyrrell Jack | Sell | 136 684 | Class A Common Stock |
INSIDER POWER |
---|
0.00 |
Last 97 transactions |
Buy: 583 544 | Sell: 71 137 085 |
Regencell Bioscience 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-769 687 (0.00 %) |
EPS: | $-0.450 |
FY | 2023 |
营收: | $0 |
毛利润: | $-769 687 (0.00 %) |
EPS: | $-0.450 |
FY | 2022 |
营收: | $0 |
毛利润: | $-604 397 (0.00 %) |
EPS: | $-0.570 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-0.107 |
Financial Reports:
No articles found.
Regencell Bioscience Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.180 | 2009-06-02 |
Last Dividend | $0.220 | 2018-02-15 |
Next Dividend | $0 | N/A |
Payout Date | 2018-02-26 | |
Next Payout Date | N/A | |
# dividends | 36 | -- |
Total Paid Out | $7.52 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.86 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2009 | $0 | 0.00% |
2010 | $0 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
Unable to generate commentary due to missing data.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Royal | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0 | 1.500 | 0 | 0 | [0 - 0.5] |
returnOnAssetsTTM | -0.465 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -0.660 | 1.500 | -8.44 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 19.15 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 19.15 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.58 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0367 | -1.500 | 9.39 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.118 | 2.00 | 9.96 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.118 | 2.00 | 9.94 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0385 | -1.500 | 9.85 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0 | 1.000 | -3.33 | -3.33 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0 | 1.000 | -2.00 | -2.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 3.32 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 4.59 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -11.81 | 1.000 | -1.294 | 0 | [1 - 100] |
returnOnEquityTTM | -0.660 | 2.50 | -5.43 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.118 | 2.00 | 9.96 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.118 | 2.00 | 9.96 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.268 | 1.500 | -5.12 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0 | 1.000 | -2.50 | 0 | [0.1 - 0.5] |
Total Score | -0.147 |
Regencell Bioscience
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。